PCT







INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6:

C12N 15/31, 15/62, C07K 14/22, 19/00, A61K 39/095

(11) International Publication Number:

WO 99/55875

(43) International Publication Date:

4 November 1999 (04.11.99)

(21) International Application Number:

PCT/US99/09486

A3

(22) International Filing Date:

29 April 1999 (29.04.99)

(30) Priority Data:

ľ

60/083,405

29 April 1998 (29.04.98)

US

(71) Applicant (for all designated States except US): AMERICAN CYANAMID COMPANY [US/US]; Five Giralda Farms, Madison, NJ 07940 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): METCALF, Thomas, N., III [US/US]; 10 Caywood Lane, Fairport, NY 14450 (US). ZAGURSKY, Robert, J. [US/US]; 569 Fox Hunt Drive, Victor, NY 14564 (US). OOI, Peggy [US/US]; 494 Main Street Fishers, Mendon, NY 14506 (US).

(74) Agents: GORDON, Alan, M.; American Home Products Corporation, Patent Law Dept. - 2B2, One Campus Drive, Parsippany, NJ 07054 (US) et al.

(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI. FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published


With international search report.

Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.

(88) Date of publication of the international search report:

13 April 2000 (13.04.00)

(54) Title: VACCINES CONTAINING RECOMBINANT PILIN AGAINST NEISSERIA GONORRHOEAE OR NEISSERIA MENINGI-TIDIS



(57) Abstract

The pilE genes of each of Neisseria gonorrhoeae and Neisseria meningitidis are cloned and their corresponding recombinant pilin proteins are expressed. In addition, a chimeric pilE gene is constructed in which the region of the pilE gene of Neisseria meningitidis class I encoding the amino-terminal region of the pilin protein is replaced by the corresponding region of the pilE gene of Neisseria gonorrhoeae. The recombinant meningococcal chimeric class I pilin protein is expressed at higher levels than the pilin protein expressed by the full-length pilE gene of Neisseria meningitidis. Furthermore, a chimeric pilE gene is constructed in which the region of the pilE gene of Neisseria meningitidis class II encoding the carboxy-terminal region of the pilin protein is replaced by the corresponding region of the pilE gene of Neisseria gonorrhoeae. The recombinant pilin proteins are used in vaccines to protect against disease caused by Neisseria gonorrhoeae or Neisseria meningitidis.

BEST AVAILABLE COPY

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
ΑU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JР	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/31 C12N15/62

C07K14/22

C07K19/00

A61K39/095

According to international Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUM	ENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	BUCHANAN, T.M. ET AL: "Development of a vaccine to prevent gonorrhea. BACTERIAL VACCINES.", SEMIN. INFECT. DIS., (1982) PP. 160-164. ISBN: 0-86577-020-0., U.S. PUBLIC HEALTH SERV. HOSP., SEATTLE, WA 98195, USA XP002118827	1,2,7-9, 15
Y	page 160, right-hand column -page 161, left-hand column page 162, right-hand column, line 26-33	7,8,13
X Y	US 4 443 431 A (BUCHANAN THOMAS M ET AL) 17 April 1984 (1984-04-17) column 2, line 49-55 column 7, line 54 -column 8, line 8 table 2	1,2,7-9, 15 7,8,13
	-/	

Further documents are listed in the continuation of box C.	Patent family members are listed in annex.
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed	"T" later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person sidiled in the art. "&" document member of the same patent family
Date of the actual completion of the international search 10 February 2000	Date of mailing of the international search report 2 5. 02. 00
Name and mailing address of the ISA European Patent Office, P.B. 5816 Patentiaan 2 NL – 2280 HV Rijewijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016	Authorized officer van de Kamp, M

Inten PCT/US 99/09486

		PCT/US 99/09486
C.(Continu	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 94 00153 A (GARCON JOHNSON NATHALIE MARIE ;PRIEELS JEAN PAUL (BE); SMITHKLINE) 6 January 1994 (1994-01-06) the whole document page 5, line 9 claim 6	7,8
Y	GUPTA R K ET AL: "Adjuvants for human vaccines—current status, problems and future prospects" VACCINE, vol. 13, no. 14, 1 October 1995 (1995-10-01), page 1263-1276 XP004057427 ISSN: 0264-410X abstract page 1264, left-hand column, paragraph 2 page 1269, left-hand column, line 4-6 page 1271, left-hand column	7,8
Y	MARINARO ET AL.: "Interleukin-12 alters helper T-cell subsets and antiody profiles induced by the mucosal adjuvant cholera toxin" ANN N Y ACAD SCI, vol. 795, 31 October 1996 (1996-10-31), page 361-365 XP002117955 page 362, line 3-6 page 362, paragraph 3 -page 363, paragraph 1 page 364, paragraph 2	7,8
Y	WO 85 04654 A (SCRIPPS CLINIC RES) 24 October 1985 (1985-10-24) example 5	13
X Y	WO 94 08013 A (OREGON STATE) 14 April 1994 (1994-04-14) page 3-6	1,3,4, 10,12,15 5,6,11, 14, 28-30, 33-42
X Y	WO 93 11791 A (OREGON STATE) 24 June 1993 (1993-06-24) page 5-7	1,3,4, 10,12,15 5,6,11, 14, 28-30, 33-42
	-/	

C.(Continu	etion) DOCUMENTS CONSIDERED TO BE RELEVANT	
degory °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	POTTS & SAUNDERS: "Nucleotide sequence of the structural gene for class I pilin from Neisseria meningitidis: homologies with the pilE locus of Neisseria gonorrhoeae" MOLECULAR MICROBIOLOGY, vol. 2, no. 5, 1988, pages 647-653,	16-27
	XP002117231 the whole document figure 3	6,11,14
	VIRJI ET AL.: "Pilus-facilitated adherence of Neisseria meningitidis to human epithelial cells: modulation of adherence phenotype occurs concurrently with changes in primary amino acid sequence and the glycosylation status of pilin" MOLECULAR MICROBIOLOGY, vol. 10, no. 5, December 1993 (1993-12),	16-27
	pages 1013-1028, XP000867896 abstract figure 6	6,11,14
	AHO ET AL.: "Characterization of a class II pilin expression locus from Neisseria meningitidis: evidence for increased diversity among pilin genes in pathogenic Neisseria species" INFECTION & IMMUNITY, vol. 65, no. 7, July 1997 (1997-07), pages 2613-2620, XP002129888 cited in the application	31,32
	abstract page 2617 -page 2618 figures 2,3 table 1	5,28-30, 33-42
	EP 0 049 945 A (BACTEX INC) 21 April 1982 (1982-04-21) example 7 claims 3,4,7	1-5,9, 10,12, 13,15
	PERRY ET AL.: "Structural analysis of the pile region of Neisseria gonorrhoeae P9" GENE, vol. 60, 1987, pages 85-92, XP002117230 abstract figure 3	1,2,7-9, 13,15

Inter: Application No
PCT/US 99/09486

		PCT/US 99/09486
	etion) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	SEIFERT: "Questions about gonococcal pilus phase— and antigenic variation" MOLECULAR MICROBIOLOGY, vol. 21, no. 3, 1996, pages 433-440, XP002117233 the whole document page 437, right-hand column	1,2
A	NASSIF ET AL: "Type-4 pili and meningococcal adhesiveness" GENE, vol. 192, no. 1, 11 June 1997 (1997-06-11), page 149-153 XP004115699 ISSN: 0378-1119 abstract page 151-152, paragraphs 4,6	1,3-5
A	MAKRIDES S C: "Strategies for Achieving High-Level Expression of Genes in Escherichia coli" MICROBIOLOGICAL REVIEWS, US, AMERICAN SOCIETY FOR MICROBIOLOGY, WASHINGTON, DC, vol. 60, no. 3, 1 September 1996 (1996-09-01), pages 512-538, XP002095235 ISSN: 0146-0749 page 512 -page 518, left-hand column page 524	6,18-28, 33-42
A	CARRICK C S ET AL: "The normally silent sigmapromoters upstream of the pile genes of both Neisseria gonorrhoeae and Neisseria meningitidis are functional when transferred to Pseudomonas aeruginosa" GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES, GB, ELSEVIER SCIENCE PUBLISHERS, BARKING, vol. 198, no. 1-2, 1 October 1997 (1997-10-01), pages 89-97, XP004116043 ISSN: 0378-1119 abstract figure 1	6
A	WO 92 13871 A (UNIV WASHINGTON) 20 August 1992 (1992-08-20) the whole document	1
A	WO 96 31618 A (UNIV NORTH CAROLINA) 10 October 1996 (1996-10-10) the whole document	1
	~	

	tion) DOCUMENTS CONSIDERED TO BE RELEVANT	I Poloviore Alexander
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 474 313 A (CIGB) 11 March 1992 (1992-03-11) the whole document	1



rational application No. PCT/US 99/09486

Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet) This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons: Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claims 9-14, 29 and 30 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a). Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet) This International Searching Authority found multiple inventions in this international application, as follows: see additional sheet As all required additional search fees were timely paid by the applicant, this International Search Report covers all As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.: No required additional search fees were timely paid by the applicant. Consequently, this international Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.: The additional search fees were accompanied by the applicant's protest. Remark on Protest No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1,15 (all partially); 2,7,8,9,13 (all completely)

A vaccine composition comprising isolated and purified recombinantly-expressed pilin protein from the species Neisseria gonorrhoeae, further comprising an adjuvant, diluent or carrier, the adjuvant being selected from the group consisting of aluminium hydroxide, aluminium phosphate, Stimulon QS-21, 3-0-deacylated monophosphoryl lipid A, Il-12, and wild-type or mutant cholera toxin, and methods of immunisation and preparation.

2. Claims: 1,3,10,12,15 (all partially); 4 (completely)

A vaccine composition comprising isolated and purified recombinantly-expressed class I pilin protein from the species Neisseria meningitidis, and methods of immunisation and preparation.

Claims: 1,3,10,12,15 (all partially); 5 (completely)

A vaccine composition comprising isolated and purified recombinantly-expressed class II pilin protein from the species Neisseria meningitidis, and methods of immunisation and preparation.

4. Claims: 1,15 (all partially); 6,11,14, 16-42 (all completely)

- A vaccine composition comprising isolated and purified recombinantly-expressed chimeric pilin protein of Neisseria gonorrhoeae and class I Neisseria meningitidis having the amino acid sequence 1-167 (or 8-167 after maturation) of SEQ ID NO:2 or a biologically equivalent amino acid sequence, and methods of immunisation and preparation. Isolated and purified encoding nucleic acids and variants (SEQ ID NO:1), plasmids, host cells, methods of production, and the isolated and purified chimeric pilin. - A vaccine composition comprising isolated and purified recombinantly-expressed chimeric pilin protein of Neisseria gonorrhoeae and class II Neisseria meningitidis having the amino acid sequence 1-170 (or 8-170 after maturation) of SEQ ID NO:4 or a biologically equivalent amino acid sequence, and methods of immunisation and preparation. Isolated and purified encoding nucleic acids and variants (SEQ ID NO:3), plasmids, host cells, methods of production, and the isolated and purified chimeric pilin.

nformation in patent family members

Application No
PCT/US 99/09486

Patent document cited in search report				Patent family member(s)	Publication date	
US	4443431	A	17-04-1984	NON	E	
WO	9400153	A	06-01-1994	AP	408 A	27-09-1995
			:	AT	156710 T	15-08-1997
				AU	1785597 A	19-06-1997
				AU	661404 B	20-07-1995
				AU	4326393 A	24-01-1994
				AU	676166 B	24-01-1994 06-03-1997
				AU		
				CA	4326493 A	24-01-1994
				CA	2138996 A	06-01-1994
				CN	2138997 A	06-01-1994
					1086142 A	04-05-1994
				CN	1092812 A	28-09-1994
				CZ	9403296 A	16-08-1995
				DE	69313134 D	18-09-1997
				DE	69313134 T	26-02-1998
				DK	671948 T	01-09-1997
				MO	9400575 A	06-01-1994
				EP	0671948 A	20-09-1995
				EP	0649470 A	26-04-1995
				EP	0761231 A	12-03-1997
				ES	2108278 T	16-12-1997
				FI	946064 A	22-02-1995
				GR	3025184 T	27-02-1998
				HU	71208 A	28-11-1995
				IL	106109 A	18-02-1997
				JP	7508512 T	21-09-1995
				JP	7508648 T	28-09-1995
				MX	9303771 A	31-05-1994
				MX	9303773 A	31-05-1994
				NO	945003 A	23-12-1994
				NZ	253137 A	27-08-1996
				NZ	253138 A	26-10-1995
				PL	170980 B	28-02-1997
				SG	49909 A	15-06-1998
				SI	9300335 A	31-12-1993
				SK	159294 A	09-08-1995
				US	5750110 A	12-05-1998
WO	8504654	Α	24-10-1985	AU	582358 B	23-03-1989
				AU	4159085 A	01-11-1985
				DK	565285 A	05-12-1985
				EP	0177583 A	16-04-1986
				FI	854839 A,B	
				IL	74829 A	28-02-1989
				JP	61501777 T	21-08-1986
				NO	854903 A	04-02-1986
				NZ	211715 A	27-01-1989
				ZA	8502629 A	27-11-1985
WO	9408013	Α	14-04-1994	AU	5403594 A	26-04-1994
WO	9311791	A	24-06-1993	AU	3416693 A	19-07-1993
EP	0049945	Α	21-04-1982	EP	0048422 A	31-03-1982
				EP	0048881 A	07-04-1982
				JP	1932813 C 6062432 B	26-05-1995 17-08-1994
				JP		

adormetors on petent family members

Inter Application No
PCT/US 99/09486

Patent document ched in search report		Publication date		Patent family member(s)	Publication date
EP 0049945	A		JP US	57081415 A 4769240 A	21-05-1982 06-09-1988
WO 9213871	A	20-08-1992	AU US	1411492 A 5834591 A	07-09-1992 10-11-1998
WO 9631618	A	10-10-1996	AU CA EP JP	5537096 A 2217522 A 0830456 A 11503322 T	23-10-1996 10-10-1996 25-03-1998 26-03-1999
EP 0474313	A	11-03-1992	CU AT AU CA DE ES FI GR JP US	22302 B 152175 T 657487 B 8368391 A 2050749 A 69125769 D 69125769 T 2103295 T 914129 A 3024127 T 6169779 A 5286484 A	02-12-1994 15-05-1997 16-03-1995 12-03-1992 08-03-1992 28-05-1997 27-11-1997 16-09-1997 08-03-1992 31-10-1997 21-06-1994 15-02-1994

Α

This Page is Inserted by IFW Indexing and Scanning Operations and is not part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS
☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
☐ FADED TEXT OR DRAWING
BLURRED OR ILLEGIBLE TEXT OR DRAWING
☐ SKEWED/SLANTED IMAGES
☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
☐ GRAY SCALE DOCUMENTS
☐ LINES OR MARKS ON ORIGINAL DOCUMENT
☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.